The study, in a rat model induced by STZ and a high-fat diet, seeks to assess whether the combined therapy of a SIRT1 direct activator along with a SIRT1 stabilizer can offer an approach to alleviate the pathophysiological features of metabolic syndrome, including insulin resistance, oxidative stress, inflammation, dyslipidemia, and hepatic lipid accumulation. This evidence concerns the gene SIRT1 and metabolic syndrome.